Mark Wittman
About Mark Wittman
Mark Wittman is the Director of BMS Discovery Chemistry at Bristol-Myers Squibb in Cambridge, MA, with 29 years of experience in drug discovery.
Company
Mark Wittman currently works at Bristol-Myers Squibb. He has held multiple roles within the company across different locations, including Director in Cambridge, MA, Research Fellow in Wallingford, CT, and Sr Principal Scientist in Wallingford, CT, USA.
Title
Mark Wittman holds the title of Director at Bristol-Myers Squibb. He is responsible for overseeing BMS Discovery Chemistry in Cambridge, MA, a role he has been in since July 2019. Additionally, he has held titles such as Research Fellow, Sr Principal Scientist, Group Leader, and various research investigation positions within the company.
Education and Expertise
Mark Wittman has an extensive educational background in chemistry. He achieved his Bachelor's of Science in Chemistry with a minor in biology from Houghton College (1979-1983). He earned his Ph.D. in Organic Synthesis from Syracuse University (1983-1988), followed by postdoctoral studies in Organic Chemistry at Yale University (1988-1990). He has 29 years of experience in drug discovery, focusing on therapeutics ranging from natural products to small molecule kinase inhibitors and specializing in oncology and immuno-oncology.
Background
Mark Wittman began his career at Bristol-Myers Squibb in 1990, taking on various research roles over the years such as Research Investigator I & II, Sr Research Investigator I & II, and Group Leader in Discovery Chemistry. His work primarily focused on drug discovery and development, particularly within oncology and immuno-oncology. He has demonstrated proficiency in leading multi-site international teams and has a proven track record in employee development.
Achievements
Mark Wittman has amassed significant achievements over his long tenure at Bristol-Myers Squibb. Notably, he has contributed to the field of drug discovery for oncology and immuno-oncology therapeutics. His capability in leading international teams and his dedication to developing staff are well-documented, reflecting his commitment to both scientific and organizational excellence. His career progression within Bristol-Myers Squibb, including reaching the role of Director of BMS Discovery Chemistry in 2019, highlights his continued impact in his field.